Salvectors' Oncolytic Bacteria Therapy YB1-X7 Receives Dual IND Clearance in US and China
核心洞察
Salvectors (搜索) has received IND clearance from China's NMPA for YB1-X7 Injection (搜索), an innovative oncolytic bacteria therapy for solid tumors (搜索).
The therapy has now obtained regulatory approval to begin clinical trials in both the United States and China, marking a significant milestone in global development.
Porton Advanced (搜索) served as the exclusive CDMO partner, providing comprehensive bacterial CMC services including strain construction and GMP production.
Salvectors (搜索)' oncolytic bacteria therapy YB1-X7 Injection (搜索) has achieved a significant regulatory milestone, receiving Investigational New Drug (IND) clearance from China's National Medical Products Administration (NMPA). The approval from the Center for Drug Evaluation marks the therapy's successful dual-country regulatory achievement, having previously obtained IND clearance in the United States.
Novel Bacterial Therapy Platform
YB1-X7 Injection (搜索) represents an innovative approach to cancer treatment, utilizing Salmonella bacteria (搜索) as a drug delivery platform specifically designed for solid tumors (搜索). Shaoxing Salvectors Biotechnology Ltd. (搜索), the developer behind this therapy, has built its drug development strategy around the YB1-v3.0 (搜索) Salmonella bacteria carrier platform.
The dual IND clearance enables Salvectors (搜索) to initiate clinical trials in both major markets simultaneously, potentially accelerating the global development timeline for this novel oncolytic bacteria therapy.
Comprehensive CDMO Partnership
Porton Advanced (搜索), a leading cell and gene therapy contract development and manufacturing organization (CDMO), served as the exclusive manufacturing partner for the YB1-X7 project. The company provided end-to-end bacterial CMC services encompassing strain construction, process development, GMP production, quality studies, release testing, and regulatory submission support.
The manufacturing process incorporated several critical elements to ensure product quality and safety. Porton Advanced (搜索) utilized an integrated production process designed to maintain the stability, activity, and safety of the bacterial samples. The company's robust testing capabilities enabled thorough purity testing and quality control throughout the manufacturing process.
Advanced Manufacturing Capabilities
A key innovation in the manufacturing process involved the development of a novel purification method specifically designed to address the unique challenges of bacterial therapeutics. This purification approach effectively removes process-related impurities while maintaining high product recovery rates and preserving strain viability - critical factors for the success of live bacterial therapies.
Porton Advanced (搜索)'s expertise extends across various bacterial therapeutic platforms, including both Gram-negative and Gram-positive bacteria, as well as aerobic and anaerobic bacterial systems. The company's integrated CDMO offerings span the complete development and manufacturing spectrum, from microbial banking through aseptic filling to final injectable product finishing.
Global Clinical Development Platform
The successful dual IND filing demonstrates the effectiveness of Porton Advanced (搜索)'s full-service investigational new drug platform, developed in collaboration with leading contract research organization partners. This integrated approach enables biotechnology companies to accelerate the translation of research discoveries into clinical applications across multiple regulatory jurisdictions.
Porton Advanced (搜索) operates state-of-the-art, GMP-compliant facilities spanning 215,000 square feet across dual headquarters in Cranbury, New Jersey, and Suzhou, China. The facilities house 10 viral vector production lines, 12 cell therapy production suites, and multiple clean rooms designed to support various stages of drug development from early research through commercialization.